Matrix metalloproteinases and coronary artery diseases

Clinical Cardiology

Volumn 26, Issue 2, 2003, Pages 55-59

  Ikeda, Uichi ^a   Shimada, Kazuyuki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute coronary syndrome; Atherosclerosis; Plaque rupture; Restenosis

Indexed keywords

ADENOVIRUS VECTOR; AMLODIPINE BESYLATE; CALCIUM CHANNEL BLOCKING AGENT; COLLAGENASE 3; FLUINDOSTATIN; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERSTITIAL COLLAGENASE; LACIDIPINE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; NIFEDIPINE; PLACEBO; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACUTE HEART INFARCTION; ANTIOXIDANT ACTIVITY; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME BLOOD LEVEL; EXTRACELLULAR MATRIX; GENE THERAPY; HEART VENTRICLE REMODELING; HUMAN; HYPERLIPIDEMIA; NONHUMAN; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; UNSTABLE ANGINA PECTORIS; VIRAL GENE DELIVERY SYSTEM;

EID: 0037312548     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960260203     Document Type: Review

References (56)

1. Creemers EEJM, Cleutjens JPM, Smits JFM, Daemen MJAP: Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure. Circ Res 2001;89:201-210
2. Lijnen HR, Collen D: Matrix metalloproteinase system deficiencies and matrix degradation. Thromb Haemost 1999;82:837-845
3. Dollery CM, McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868
4. George SJ: Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Exp Opin Invest Drugs 2000;9:993-1007
5. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM: IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995;96:2304-2310
6. Sasaguri T, Arima N, Tanimoto A, Shimajiri S, Hamada T, Sasaguri Y: A role for interleukin 4 in production of matrix metalloproteinase 1 by human aortic smooth muscle cells. Atherosclerosis 1998;138:247-253
7. Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG: Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-γ. J Clin Invest 1990;86:1204-1210
8. Malik N, Greenfield BW, Wahl AF, Kiener PA: Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996; 156:3952-3960
9. Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P: Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by lymphocytes. A role for CD40 signaling in plaque rupture? Circ Res 1997;81:448-454
10. Lee E, Grodzinsky AJ, Libby P, Clinton SK, Lark MW, Lee RT: Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. Arterioscler Thromb Vasc Biol 1995;15:2284-2289
11. Hojo Y, Ikeda U, Takahashi M, Sakata Y, Takizawa T, Okada K, Saito T, Shimada K: Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells. J Mol Cell Cardiol 2000;32:1459-1468
12. Lijnen HR: Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001;86:324-333
13. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996;98:2572-2579
14. Galis ZS, Asanuma K, Godin D, Meng X: N-Acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: New target for antioxidant therapy. Circulation 1998;97:2445-2453
15. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, Shah PK: Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999;99:993-998
16. Ikeda U, Takahashi M, Shimada K: Monocyte-endothelial cell interaction in atherogenesis and thrombosis. Clin Cardiol 1998;21:11-14
17. Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D: Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998;18:1035-1045
18. Lijnen HR, Soloway P, Collen D: Tissue inhibitor of matrix metalloproteinase-1 impairs arterial neointima formation after vascular injury in mice. Circ Res 1999;85:1186-1191
19. Galis ZS, Sukhova GK, Kranzohofer R, Clark S, Libby P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995;92:402-406
20. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atheroslcerotic plaques: Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92:1565-1569
21. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S: Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991;88:8154-8158
22. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atheroslcerotic plaques. J Clin Invest 1994;94:2493-2503
23. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P: Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995;748:501-507
24. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, Clowes AW: Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995;92:1393-1398
25. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus HG, Wickline SA, Parks WC: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996;93:9748-9753
26. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, Stetler-Stevenson WG, Froehlich J, Lakatta EG: Increased expression of 72-kd type IV collagenase (MMP-2) in human atherosclerotic lesions. Am J Pathol 1996;148:121-128
27. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DP, Teepen H, van der Wal AC, Borst C: Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000;150:245-253
28. Pasterkamp JG, Schoneveld AH, Hijnen DJ, de Kleijn DPV, Teepen H, van der Wal AC, Borst C: Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000;150:245-253
29. Shu YE, Humphries S, Henney A: Matrix metalloproteinases: Implication in vascular matrix remodeling during atherogenesis. Clin Sci 1998;94:103-110
30. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000;101:1833-1839
31. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM: Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995;91:2125-2131
32. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T: Peripheral blood levels of matrix metalloproteinases-2 and 9 are elevated in patients with acute myocardial syndrome. J Am Coll Cardiol 1998;32:368-372
33. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K: Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-217
34. Hirohata S, Kusachi S, Murakami M, Murakami T, Sano I, Watanabe T, Komatsubara I, Kondo J, Tsuji T: Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute coronary syndrome. Heart 1997;78:278-284
35. Hojo Y, Ikeda U, Ueno S, Arakawa H, Shimada K: Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001:65:71-75
36. James TW, Wagner R, White LA, Zwolak RM, Brinkerhoff CE: Induction of collagenase and stromelysin gene expression by mechanical injury in vascular smooth muscle-derived cell line. J Cell Physiol 1993;157:426-437
37. Bendeck MP, Zempo N, Clowes AV, Galardy RE, Reidy MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994;75:539-545
38. Southgate KM, Fisher M, Banning AP, Thurston VJ, Baker AH, Fabunmi RP, Grove PH, Davies M, Newby AC: Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res 1996;79:1177-1187
39. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW: Release of gelatinase A during platelet activation mediates aggregation. Nature 1997;386:616-619
40. Cheng L, Mantile G, Pauly R, Nater C, Felici A, Monticone R, Bilato C, Gluzband YA, Crow MT, Stetler-Stevenson W, Capogrossi MC: Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 1998;98:2195-2201
41. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, Shimada K: Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 2002;161:185-192
42. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-1678
43. Ikeda U, Shimpo M, Ohki R, Inaba H, Takahashi M, Yamamoto K, Shimada K: Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000;36:325-329
44. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-999
45. Ikeda U, Shimada K: Pleiotropic effects of statins on the vascular tissue. Curr Drug Targets - Cardiovasc Haematol Dis 2001;1:51-58
46. Mason PP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1993;31:275-281
47. Ikeda U, Hojo Y, Ueno S, Arakawa H, Shimada K: Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human endothelial cells. J Cardiovasc Pharmacol 2000;35:887-890
48. Herbette LG, Gaviraghi G, Tulenko T, Mason RP: Molecular interaction between lacidipine and biological membranes. J Hypertens 1993;11:S13-19
49. Bellosta S, Canavesi M, Favari E, Cominacini L, Gaviraghi G, Fumagalli R, Paoletti R, Bernini F: Lalsoacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. J Pharmacol Exp Ther 2001;296:736-743
50. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller ME, Riley W: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000;102:1503-1510
51. Jorgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J, Webb J, Buller C, Goulet G, Erikssen J, Thaulow E: Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: Results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2000;35:592-599
52. Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW: Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res 1996;79:812-820
53. Dollery CM, Humphries SE, McClelland A, Latchman DS, Mcewan JR: Expression of tissue inhibitor of matrix metalloproteinase 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 1999;99:3199-3205
54. Rouis M, Adamy C, Duverger N, Lesnik P, Horellou P, Moreau M, Emmanuel F, Caillaud JM, Laplaud PM, Dachet C, Chapman MJ: Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999;100:533-540
55. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH: Inhibition of late vein graft neointimal formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000;101:296-304
56. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH: Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998;9:867-877